Squamous Cell Carcinoma Equipment & Supplies
97 equipment items found
Manufactured by:Creative BioMart  based in, NEW YORK (USA)
Keratin 8 belongs to the type B (basic) subfamily of high molecular weight keratins and exists in combination with keratin 18. Keratin 8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin ...
by:Alfa Cytology  based inU.S. VIRGIN ISLANDS
KP372-1 is an Akt inhibitor that inhibits proliferation and induces apoptosis and anoikis. KP372-1 is also an NQO1 redox cycling agent that causes DNA damage (including DNA breakage) by generating ROS. KP372-1 can be used in cancer research (such as head and neck squamous cell carcinoma (HNSCC) and pancreatic cancer). ...
Manufactured by:Medinfar Group  based inAmadora, PORTUGAL
Actinic Keratosis is a very common skin disease characterized by superficial lesions, which appear on skin that has been exposed to the sun. (1);(2). Actinic Keratosis are deemed pre-cancerous lesions because they can evolve into squamous cell carcinoma. As such, ALL ACTINIC KERATOSIS MUST BE TREATED. Actinic Keratosis usually appear as one or more brownish red spots with a scaly surface. The ...
Manufactured by:EDM3 Solutions  based inJacksonville, FLORIDA (USA)
Tissue staining is the cornerstone of Mohs Micrographic Surgery (MMS). EDM3s new “all inclusive” Mohs Lab Staining Kit, will consistently yield slides with the highest quality, excellent morphology and differentiation of target cellular components. The kit includes marking dyes, freezing medium, bleaching reagents, both Hematoxylin and Eosin (H&E) and Toluidine Blue (T-blue) ...
Manufactured by:GeneCentric Therapeutics, Inc.  based inDurham, NORTH CAROLINA (USA)
Bladder cancer is one of the most common types of cancer which like lung and other cancers, is quite heterogeneous. Bladder cancer occurs more frequently in men than women, generally at an older age, and is more common among smokers than non-smokers. The most common type of bladder cancer begins within cells that line the inside of the bladder, urothelial cells – also called transitional ...
Manufactured by:Episkin  based inLyon Cedex 7, FRANCE
The SkinEthicTM HOE model is composed of TR146 cells (derived from a squamous cell carcinoma of the buccal mucosa) cultivated on an inert polycarbonate filter at the air liquid interface in a chemically defined medium. This model forms an epithelial tissue devoid of stratum corneum, resembling histologically to the mucosa of the oral ...
Manufactured by:Holostem Terapie Avanzate S.r.l.  based inModena, ITALY
Epidermolysis Bullosa (EB) is a group of genetic adhesion disorders characterized by fragility of the skin. EB are devastating, highly disfiguring, blistering pathologies that severely impairs the quality of life of patients and affect approximately 500,000 people worldwide ...
Manufactured by:Fujirebio  based inMalvern, PENNSYLVANIA (USA)
CanChek Tumor Marker Control Serum is intended for use as an assayed quality control serum to monitor the accuracy of laboratory testing for neuron specific enolase (NSE), S100B protein and squamous cell carcinoma antigen (SCCA). The use of a quality control serum is indicated to verify the performance characteristics of an in vitro diagnostic laboratory test and is an integral part of good ...
by:Traws Pharma  based inNewtown, PENNSYLVANIA (USA)
Rigosertib is a small molecule that inhibits multiple cellular signaling pathways driving cancer cell growth while having little effect on normal cells. In contrast to many kinase inhibitors, rigosertib does not interact at the ATP binding site, but acts via allosteric inhibition. Rigosertib has the potential to affect three critical pathways for cancer cell proliferation and survival: the ...
Manufactured by:GeneCentric Therapeutics, Inc.  based inDurham, NORTH CAROLINA (USA)
Head and Neck Cancer, a group of cancers that starts within the mouth, nose, throat, larynx, sinuses, or salivary glands, is the seventh most common of all cancers. Because most majority begin in squamous cells which line the moist surfaces inside the head and neck areas, such cancers are also referred to as Head and Neck Squamous Cell Carcinomas ...
Manufactured by:AVITA Medical  based inValencia, CALIFORNIA (USA)
Epidermolysis Bullosa (EB) is a group of rare and incurable skin disorders caused by mutations in genes encoding structural proteins resulting in skin fragility and blistering, leading to chronic wounds and, in some sub-types, an increased risk of squamous cell carcinoma or death. Dystrophic EB is estimated to affect 3-8 million people[1], and there is currently no FDA-approved ...
Manufactured by:GeneCentric Therapeutics, Inc.  based inDurham, NORTH CAROLINA (USA)
GeneCentric has developed two gene expression profilers (LSP 210 and LSP 220) that define molecular subtypes of the two most common forms of non-small cell lung cancer (NSCLC), squamous cell carcinoma, and ...
Manufactured by:Radiopharm Theranostics  based inCarlton, AUSTRALIA
Nano-mAbs is the invention of Dr Hong Hoi Ting, an internationally regarded radiopharmaceutical and nuclear medicine expert, formerly from the University of ...
Manufactured by:AVEO Pharmaceuticals, Inc.  based inBoston, MASSACHUSETTS (USA)
Ficlatuzumab (formerly known as AV-299) is a potent hepatocyte growth factor (HGF) immunoglobulin G1 (IgG1) inhibitory antibody that binds to the HGF ligand with high affinity and specificity. HGF is the natural ligand of c-Met and blocking HGF inhibits signaling through the HGF/c-Met signaling ...
Manufactured by:Theriva Biologics, Inc., formely known as ynthetic Biologics, Inc.  based inRockville, MARYLAND (USA)
Building on the clinical advancement of VCN-01, Theriva developed the Albumin Shield™ technology to protect oncolytic viruses from circulating anti-oncolytic virus antibodies after systemic administration. We anticipate that this technology will enable multiple oncolytic virus doses to be administered in therapeutic cycles to treat particularly refractory ...
Manufactured by:MEDlight GmbHÂ Â based inHERFORD, GERMANY
Painfree Compact Daylight PDT; Enhanced conventional PDT; Large adjustable treament area; New touchscreen with many features; Highly flexible and adjustable device arm; Premium design with durable high quality ...
Manufactured by:Shanghai Henlius Biotech, Inc  based inShanghai, CHINA
(serplulimab injection, anti-PD-1 mAb), company’s first self-developed innovative monoclonal antibody, was approved by the NMPA for the treatment of Microsatellite Instability-High (MSI-H) solid tumors in March 2022, providing an alternative treatment option for patients with MSI-H solid tumors. Henlius actively promotes HANSIZHUANG in conjunction with in-house products of the company and ...
by:Castle Biosciences, Inc.  based inFriendswood, TEXAS (USA)
Predicting Individual Risk of Metastasis: DecisionDx-SCC is now commercially available. DecisionDx-SCC is clinically validated as a significant predictor of metastasis and the strongest predictor of risk compared to traditional clinical and pathological factors. DecisionDx-SCC complements traditional prognostic risk assessment factors, enabling more informed choices about treatment and follow-up ...
Manufactured by:Xstrahl  based inNorcross, GEORGIA (US) (USA)
The Xstrahl 150 is a low-energy X-ray system designed primarily for the treatment of non-melanoma skin cancers and various superficial skin conditions. It is particularly effective for types such as basal cell carcinoma and squamous cell carcinoma, as well as benign skin conditions, including keloid scars and hyperproliferative disorders like Dupuytren's contracture. The system offers a versatile ...
Manufactured by:TC BioPharm  based inHolytown, UNITED KINGDOM
TCB006 is an allogeneic CAR-T product targeting B7-H4 for the treatment of cancers arising from solid tumors. B7-H4 antigen is overexpressed in breast cancers, especially triple negative breast cancer, and ovarian cancers, both diseases with acute clinical needs. There are 270,000 new cases of breast cancer and 23,000 new cases of ovarian cancer per year in the US. It is also implicated ...